

# Anne Barton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8768163/publications.pdf>

Version: 2024-02-01

342  
papers

33,319  
citations

14614

66  
h-index

4203

174  
g-index

359  
all docs

359  
docs citations

359  
times ranked

35406  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. <i>Nature</i> , 2007, 447, 661-678.	13.7	8,895
2	Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes. <i>Science</i> , 2007, 316, 1336-1341.	6.0	2,040
3	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	13.7	1,974
4	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	18.1	1,441
5	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. <i>Nature Genetics</i> , 2007, 39, 1329-1337.	9.4	1,298
6	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010, 42, 508-514.	9.4	1,132
7	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010, 42, 985-990.	9.4	918
8	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012, 44, 1341-1348.	9.4	848
9	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010, 464, 713-720.	13.7	737
10	Meta-analysis and imputation refines the association of 15q25 with smoking quantity. <i>Nature Genetics</i> , 2010, 42, 436-440.	9.4	581
11	A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci. <i>PLoS Genetics</i> , 2008, 4, e1000041.	1.5	572
12	High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. <i>Nature Genetics</i> , 2012, 44, 1336-1340.	9.4	558
13	Rheumatoid arthritis association at 6q23. <i>Nature Genetics</i> , 2007, 39, 1431-1433.	9.4	361
14	Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. <i>Nature Genetics</i> , 2010, 42, 996-999.	9.4	334
15	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. <i>Nature Genetics</i> , 2009, 41, 1313-1318.	9.4	306
16	Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: Further support that PTPN22 is an autoimmunity gene. <i>Arthritis and Rheumatism</i> , 2005, 52, 1694-1699.	6.7	266
17	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 69-74.	0.5	240
18	Whole-Genome Scan, in a Complex Disease, Using 11,245 Single-Nucleotide Polymorphisms: Comparison with Microsatellites. <i>American Journal of Human Genetics</i> , 2004, 75, 54-64.	2.6	209

#	ARTICLE	IF	CITATIONS
19	Human SNP Links Differential Outcomes in Inflammatory and Infectious Disease to a FOXO3-Regulated Pathway. <i>Cell</i> , 2013, 155, 57-69.	13.5	200
20	A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. <i>Arthritis and Rheumatism</i> , 2004, 50, 1117-1121.	6.7	186
21	Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. <i>Arthritis and Rheumatism</i> , 2002, 46, 632-639.	6.7	184
22	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. <i>Rheumatology</i> , 2014, 53, 213-222.	0.9	177
23	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1202-1210.	0.5	166
24	Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 359-369.	6.7	161
25	Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci. <i>Nature Communications</i> , 2015, 6, 10069.	5.8	161
26	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015, 6, 6046.	5.8	149
27	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	1.5	146
28	Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. <i>Nature Genetics</i> , 2008, 40, 1156-1159.	9.4	143
29	Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. <i>Arthritis and Rheumatism</i> , 2011, 63, 645-653.	6.7	143
30	Recent advances in the genetics of RA susceptibility. <i>Rheumatology</i> , 2007, 47, 399-402.	0.9	138
31	Optimisation of methods for bacterial skin microbiome investigation: primer selection and comparison of the 454 versus MiSeq platform. <i>BMC Microbiology</i> , 2017, 17, 23.	1.3	133
32	Translational genomics and precision medicine: Moving from the lab to the clinic. <i>Science</i> , 2019, 365, 1409-1413.	6.0	133
33	Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. <i>Human Molecular Genetics</i> , 2008, 17, 2274-2279.	1.4	131
34	Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 463-468.	0.5	130
35	Statistical colocalization of genetic risk variants for related autoimmune diseases in the context of common controls. <i>Nature Genetics</i> , 2015, 47, 839-846.	9.4	128
36	Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 3705-3709.	6.7	122

#	ARTICLE	IF	CITATIONS
37	TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits. <i>PLoS ONE</i> , 2015, 10, e0122271.	1.1	120
38	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1645.	3.8	119
39	Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. <i>Arthritis and Rheumatism</i> , 2001, 44, 61-65.	6.7	118
40	Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. <i>Human Molecular Genetics</i> , 2008, 17, 3532-3538.	1.4	111
41	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1641-1644.	0.5	103
42	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95
43	Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1375-1381.	0.5	94
44	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. <i>Human Molecular Genetics</i> , 2009, 18, 2693-2699.	1.4	93
45	Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 251-257.	6.7	93
46	Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1984-1990.	0.5	93
47	Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 677-682.	0.5	92
48	Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. <i>Arthritis Research and Therapy</i> , 2010, 12, R175.	1.6	92
49	Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2013, 13, 227-234.	0.9	91
50	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Rheumatology</i> , 2015, 54, 494-499.	0.9	90
51	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
52	Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1029-1035.	0.5	89
53	Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. <i>Arthritis and Rheumatism</i> , 2009, 60, 2565-2576.	6.7	86
54	Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23. <i>Genome Biology</i> , 2016, 17, 212.	3.8	85

#	ARTICLE	IF	CITATIONS
55	The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register. <i>Arthritis and Rheumatism</i> , 2007, 56, 2929-2935.	6.7	84
56	Rare, Low-Frequency, and Common Variants in the Protein-Coding Sequence of Biological Candidate Genes from GWASs Contribute to Risk of Rheumatoid Arthritis. <i>American Journal of Human Genetics</i> , 2013, 92, 15-27.	2.6	83
57	Genetic susceptibility to rheumatoid arthritis: An emerging picture. <i>Arthritis and Rheumatism</i> , 2009, 61, 1441-1446.	6.7	79
58	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. <i>Human Molecular Genetics</i> , 2009, 18, 2518-2522.	1.4	78
59	Informed Conditioning on Clinical Covariates Increases Power in Case-Control Association Studies. <i>PLoS Genetics</i> , 2012, 8, e1003032.	1.5	78
60	Genetic and epigenetic predictors of responsiveness to treatment in RA. <i>Nature Reviews Rheumatology</i> , 2014, 10, 329-337.	3.5	78
61	Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. <i>Genes and Immunity</i> , 2003, 4, 487-491.	2.2	76
62	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFAB signalling pathways. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1315-1320.	0.5	74
63	PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 666-670.	0.5	73
64	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	5.8	73
65	Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. <i>Seminars in Immunopathology</i> , 2017, 39, 395-408.	2.8	73
66	Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). <i>Arthritis Research and Therapy</i> , 2018, 20, 147.	1.6	73
67	Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. <i>Arthritis and Rheumatism</i> , 2009, 60, 258-263.	6.7	72
68	Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 861-868.	1.5	71
69	Increased DNA methylation variability in rheumatoid arthritis-discordant monozygotic twins. <i>Genome Medicine</i> , 2018, 10, 64.	3.6	71
70	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1016-1019.	0.5	68
71	MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. <i>Pharmacogenomics Journal</i> , 2013, 13, 137-147.	0.9	67
72	Genetics of immune-mediated inflammatory diseases. <i>Clinical and Experimental Immunology</i> , 2018, 193, 3-12.	1.1	66

#	ARTICLE	IF	CITATIONS
73	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3596-3602.	6.7	65
74	Replication of association of the <i>PTPRC</i> gene with response to anti-tumor necrosis factor therapy in a large UK cohort. <i>Arthritis and Rheumatism</i> , 2012, 64, 665-670.	6.7	65
75	HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 807-811.	0.5	64
76	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1882-1885.	0.5	64
77	Variants in <i>RUNX3</i> Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1224-1231.	6.7	63
78	Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 813-816.	0.5	62
79	Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1049-1053.	0.5	61
80	Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R12.	1.6	60
81	Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. <i>British Journal of Dermatology</i> , 2012, 166, 474-482.	1.4	59
82	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1353-1360.	2.9	59
83	Genetic and genomic predictors of anti-TNF response. <i>Pharmacogenomics</i> , 2011, 12, 1571-1585.	0.6	57
84	<i>Mycobacterium marinum</i> infection causing septic arthritis and osteomyelitis. <i>Rheumatology</i> , 1997, 36, 1207-1209.	0.9	55
85	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1054-1057.	0.5	55
86	Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 98-103.	0.5	55
87	Predicting the Risk of Rheumatoid Arthritis and Its Age of Onset through Modelling Genetic Risk Variants with Smoking. <i>PLoS Genetics</i> , 2013, 9, e1003808.	1.5	55
88	A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 170-176.	0.5	55
89	Association of the <i>AFF3</i> gene and <i>IL2/IL21</i> gene region with juvenile idiopathic arthritis. <i>Genes and Immunity</i> , 2010, 11, 194-198.	2.2	54
90	High resolution linkage and association mapping identifies a novel rheumatoid arthritis susceptibility locus homologous to one linked to two rat models of inflammatory arthritis. <i>Human Molecular Genetics</i> , 2001, 10, 1901-1906.	1.4	52

#	ARTICLE	IF	CITATIONS
91	Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. <i>British Journal of Dermatology</i> , 2020, 182, 130-137.	1.4	52
92	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1774-1779.	0.5	51
93	Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 748-752.	6.7	50
94	Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 678-684.	2.9	50
95	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 208-213.	0.5	49
96	One SNP at a Time: Moving beyond GWAS in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 567-573.	0.3	48
97	A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis. <i>Rheumatology</i> , 2000, 39, 63-66.	0.9	43
98	Brief Report: Identification of <i>BACH2</i> and <i>RAD51B</i> as Rheumatoid Arthritis Susceptibility Loci in a Meta-Analysis of Genome-Wide Data. <i>Arthritis and Rheumatism</i> , 2013, 65, 3058-3062.	6.7	43
99	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1364-1371.	0.9	43
100	Precision Medicine in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 377-387.	0.8	42
101	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2018, 18, 528-538.	0.9	42
102	Investigation of association between the TRAF family genes and RA susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1322-1326.	0.5	41
103	Novel Rheumatoid Arthritis Susceptibility Locus at 22q12 Identified in an Extended UK Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 24-30.	2.9	41
104	Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1139-1144.	0.5	41
105	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2018, 18, 657-664.	0.9	41
106	A restricted spectrum of missense KMT2D variants cause a multiple malformations disorder distinct from Kabuki syndrome. <i>Genetics in Medicine</i> , 2020, 22, 867-877.	1.1	41
107	Investigation of rheumatoid arthritis susceptibility loci in juvenile idiopathic arthritis confirms high degree of overlap. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1117-1121.	0.5	40
108	Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. <i>RMD Open</i> , 2016, 2, e000171.	1.8	40

#	ARTICLE	IF	CITATIONS
109	Investigation of susceptibility loci identified in the UK rheumatoid arthritis whole-genome scan in a further series of 217 UK affected sibling pairs. <i>Arthritis and Rheumatism</i> , 2004, 50, 729-735.	6.7	39
110	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1350-1354.	0.5	39
111	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1400-1409.	0.9	39
112	Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?. <i>Current Opinion in Rheumatology</i> , 2019, 31, 285-292.	2.0	39
113	Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. <i>Arthritis Care and Research</i> , 2010, 62, 664-675.	1.5	38
114	The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1118-1124.	0.5	38
115	Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort. <i>Arthritis Research and Therapy</i> , 2010, 12, R57.	1.6	37
116	CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 361-370.	2.9	37
117	Association of protein kinase C alpha (PRKCA) gene with multiple sclerosis in a UK population. <i>Brain</i> , 2004, 127, 1717-1722.	3.7	36
118	Association of the FCRL3 gene with rheumatoid arthritis: a further example of population specificity?. <i>Arthritis Research and Therapy</i> , 2006, 8, R117.	1.6	36
119	Increasing age at symptom onset is associated with worse radiological damage at presentation in patients with early inflammatory polyarthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 389-393.	0.5	36
120	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2199-2203.	0.5	36
121	Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1713-1718.	0.5	36
122	Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. <i>Human Mutation</i> , 2012, 33, 741-749.	1.1	36
123	Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. <i>Rheumatology</i> , 2013, 52, 261-266.	0.9	36
124	Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 319-323.	0.7	35
125	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. <i>Archives of Dermatological Research</i> , 2016, 308, 201-205.	1.1	35
126	Investigation of type 1 diabetes and coeliac disease susceptibility loci for association with juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2169-2172.	0.5	34

#	ARTICLE	IF	CITATIONS
127	Update on the genetic risk factors for rheumatoid arthritis. Expert Review of Clinical Immunology, 2010, 6, 61-75.	1.3	34
128	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. PLoS ONE, 2014, 9, e87645.	1.1	34
129	Investigation of the SLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients. Arthritis and Rheumatism, 2005, 52, 752-758.	6.7	33
130	The bacterial skin microbiome in psoriatic arthritis, an unexplored link in pathogenesis: challenges and opportunities offered by recent technological advances. Rheumatology, 2014, 53, 777-784.	0.9	33
131	Replication of Associations of Genetic Loci Outside the HLA Region With Susceptibility to Anti-Cyclic Citrullinated Peptide-Negative Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1603-1613.	2.9	33
132	Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2005, 64, 1311-1315.	0.5	32
133	Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. Annals of the Rheumatic Diseases, 2010, 69, 1572-1573.	0.5	32
134	The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology, 2011, 50, 78-84.	0.9	32
135	Association Between Genetic Variation in <i>FOXO3</i> and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis. Arthritis and Rheumatology, 2016, 68, 2629-2636.	2.9	32
136	Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2004, 63, 280-284.	0.5	30
137	Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. Annals of the Rheumatic Diseases, 2007, 66, 683-686.	0.5	30
138	The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK Biobank. Rheumatology, 2018, 57, 2172-2182.	0.9	30
139	Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis. Human Genetics, 2010, 128, 627-633.	1.8	29
140	Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. Biomarkers in Medicine, 2015, 9, 499-512.	0.6	29
141	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open, 2017, 3, e000314.	1.8	29
142	The use of missing values in proteomic data-independent acquisition mass spectrometry to enable disease activity discrimination. Bioinformatics, 2020, 36, 2217-2223.	1.8	29
143	A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. British Journal of Dermatology, 2011, 164, no-no.	1.4	28
144	Identifying Causal Genes at the Multiple Sclerosis Associated Region 6q23 Using Capture Hi-C. PLoS ONE, 2016, 11, e0166923.	1.1	28

#	ARTICLE	IF	CITATIONS
145	Distinct HLA Associations with Rheumatoid Arthritis Subsets Defined by Serological Subphenotype. <i>American Journal of Human Genetics</i> , 2019, 105, 616-624.	2.6	27
146	Polymorphisms in IL-1B Distinguish between Psoriasis of Early and Late Onset. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1459-1462.	0.3	26
147	Regulation of a novel $\beta$ -catenin splice variant in schizophrenic smokers. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 759-768.	1.1	25
148	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and <i>CD39</i> . <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1055-1061.	0.5	25
149	The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 251-255.	0.5	24
150	Association of the CCR5 gene with juvenile idiopathic arthritis. <i>Genes and Immunity</i> , 2010, 11, 584-589.	2.2	24
151	Genetic Variants in Toll-Like Receptors Are Not Associated with Rheumatoid Arthritis Susceptibility or Anti-Tumour Necrosis Factor Treatment Outcome. <i>PLoS ONE</i> , 2010, 5, e14326.	1.1	24
152	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013, 45, 468-469.	9.4	24
153	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1040-1047.	0.5	24
154	A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence. <i>Analyst</i> , 2015, 140, 1981-1987.	1.7	23
155	HLA-DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2618-2628.	2.9	23
156	Prediction of response to methotrexate in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 419-429.	1.3	23
157	Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1127-1134.	0.5	23
158	Genetic approaches to the investigation of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2002, 14, 260-269.	2.0	22
159	Investigation of Rheumatoid Arthritis Genetic Susceptibility Markers in the Early Rheumatoid Arthritis Study Further Replicates the <i>TRAF1</i> Association with Radiological Damage. <i>Journal of Rheumatology</i> , 2013, 40, 144-156.	1.0	22
160	Lack of Association of Variants Previously Associated with Anti-TNF Medication Response in Rheumatoid Arthritis Patients: Results from a Homogeneous Greek Population. <i>PLoS ONE</i> , 2013, 8, e74375.	1.1	22
161	A rare coding allele in <i>IFIH1</i> is protective for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1321-1324.	0.5	22
162	DNA methylation as a marker of response in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2017, 18, 1323-1332.	0.6	22

#	ARTICLE	IF	CITATIONS
163	Stratified medicine in rheumatoid arthritis—the MATURA programme. <i>Rheumatology</i> , 2017, 56, 1247-1250.	0.9	22
164	The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. <i>Rheumatology</i> , 2020, 59, 213-223.	0.9	22
165	Investigation of the MHC2TA gene, associated with rheumatoid arthritis in a Swedish population, in a UK rheumatoid arthritis cohort. <i>Arthritis and Rheumatism</i> , 2006, 54, 3417-3422.	6.7	21
166	Genetic susceptibility factors for psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 152-156.	2.0	21
167	Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. <i>Scientific Reports</i> , 2021, 11, 7266.	1.6	21
168	Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. <i>Rheumatology</i> , 2009, 48, 1369-1374.	0.9	20
169	Heterogeneity of Anticitrullinated Peptide Antibodies and Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 929-932.	1.0	20
170	Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1640-1645.	0.5	20
171	Genotypic variability based association identifies novel non-additive loci DHCR7 and IRF4 in sero-negative rheumatoid arthritis. <i>Scientific Reports</i> , 2017, 7, 5261.	1.6	20
172	Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1438-1451.	1.5	20
173	Genetic variation in CCR5 does not predict clinical outcome in inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 3615-3616.	6.7	19
174	What Have Genome-Wide Studies Told Us About Psoriatic Arthritis?. <i>Current Rheumatology Reports</i> , 2012, 14, 364-368.	2.1	19
175	Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 317-320.	0.5	19
176	Evidence for a novel rheumatoid arthritis susceptibility locus on chromosome 6p. <i>Arthritis and Rheumatism</i> , 2004, 50, 3823-3830.	6.7	18
177	Psoriatic arthritis – what the dermatologist needs to know. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1270-1277.	1.3	18
178	Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Arthritis Research and Therapy</i> , 2012, 14, R214.	1.6	18
179	Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R109.	1.6	18
180	Enrichment of vitamin D response elements in RA-associated loci supports a role for vitamin D in the pathogenesis of RA. <i>Genes and Immunity</i> , 2013, 14, 325-329.	2.2	18

#	ARTICLE	IF	CITATIONS
181	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	6.3	18
182	Machine learning in precision medicine: lessons to learn. <i>Nature Reviews Rheumatology</i> , 2021, 17, 5-6.	3.5	18
183	Polymorphisms in the mannose binding lectin (MBL) gene are not associated with radiographic erosions in rheumatoid or inflammatory polyarthritis. <i>Journal of Rheumatology</i> , 2004, 31, 442-7.	1.0	18
184	Investigation of Caucasian rheumatoid arthritis susceptibility loci in African patients with the same disease. <i>Arthritis Research and Therapy</i> , 2012, 14, R239.	1.6	17
185	Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. <i>British Journal of Dermatology</i> , 2015, 172, 933-939.	1.4	17
186	Characterisation of CD4+â€‰T-cell subtypes using single cell RNA sequencing and the impact of cell number and sequencing depth. <i>Scientific Reports</i> , 2020, 10, 19825.	1.6	17
187	Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 2908-2919.	0.9	17
188	Genetic epidemiology. Psoriatic arthritis. <i>Arthritis Research</i> , 2002, 4, 247.	2.0	16
189	The type 1 diabetes susceptibility gene SUMO4 at IDDM5 is not associated with susceptibility to rheumatoid arthritis or juvenile idiopathic arthritis. <i>Rheumatology</i> , 2005, 44, 1390-1393.	0.9	16
190	Idiopathic Orbital Inflammation Successfully Treated Using Rituximab in a Patient with Rheumatoid Arthritis: Figure 1.. <i>Journal of Rheumatology</i> , 2012, 39, 1485-1486.	1.0	16
191	Pharmacogenetics of Treatment Response in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2015, 17, 44.	2.1	16
192	HLA-DPB1-COL11A2 and three additional xMHC loci are independently associated with RA in a UK cohort. <i>Genes and Immunity</i> , 2011, 12, 169-175.	2.2	15
193	Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 313-314.	0.5	15
194	Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data. <i>Genetic Epidemiology</i> , 2018, 42, 754-771.	0.6	15
195	Predicting treatment response to IL6R blockers in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 3603-3610.	0.9	15
196	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. <i>Arthritis and Rheumatology</i> , 2022, 74, 1535-1543.	2.9	15
197	A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register. <i>Pharmacogenomics Journal</i> , 2012, 12, 128-133.	0.9	14
198	A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. <i>Rheumatology</i> , 2016, 55, 2131-2137.	0.9	14

#	ARTICLE	IF	CITATIONS
199	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , 2016, 55, 2050-2055.	0.9	14
200	Investigation of the genetic overlap between rheumatoid arthritis and psoriatic arthritis in a Greek population. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 180-186.	0.6	14
201	Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis. <i>Rheumatology</i> , 2019, 58, 1250-1258.	0.9	14
202	A re-evaluation of three putative functional single nucleotide polymorphisms in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1373-1375.	0.5	13
203	Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients. <i>Arthritis Care and Research</i> , 2010, 62, 676-682.	1.5	13
204	Identifying a novel locus for psoriatic arthritis. <i>Rheumatology</i> , 2016, 55, 25-32.	0.9	13
205	Assessing the Role of DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio in Rheumatoid Arthritis. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	13
206	Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2019, 9, 46.	1.1	13
207	Development and validation of a methotrexate adherence assay. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1192-1197.	0.5	13
208	Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between <i>IL18RAP</i> expression and treatment response. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1446-1452.	0.5	13
209	Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 338-341.	0.7	12
210	Expression of the autoimmunity associated TNFAIP3 is increased in rheumatoid arthritis but does not differ according to genotype at 6q23. <i>Rheumatology</i> , 2012, 51, 1514-1515.	0.9	12
211	Genetic feature engineering enables characterisation of shared risk factors in immune-mediated diseases. <i>Genome Medicine</i> , 2020, 12, 106.	3.6	12
212	<i>KIF3A</i> and <i>IL-4</i> are disease-specific biomarkers for psoriatic arthritis susceptibility. <i>Oncotarget</i> , 2017, 8, 95401-95411.	0.8	12
213	An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the <i>REL</i> gene. <i>British Journal of Dermatology</i> , 2013, 168, 864-866.	1.4	11
214	The role of genetic polymorphisms regulating vitamin D levels in rheumatoid arthritis outcome: a Mendelian randomisation approach. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1430-1433.	0.5	11
215	HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e51-e51.	0.5	11
216	Adding value to real-world data: the role of biomarkers. <i>Rheumatology</i> , 2020, 59, 31-38.	0.9	11

#	ARTICLE	IF	CITATIONS
217	Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy. <i>Rheumatology</i> , 2021, 60, 2355-2365.	0.9	11
218	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. <i>Arthritis Research and Therapy</i> , 2021, 23, 80.	1.6	11
219	Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. <i>Lancet, The</i> , 2015, 385, S44.	6.3	10
220	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. <i>Rheumatology</i> , 2017, 56, kew387.	0.9	10
221	Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS. <i>Journal of Rheumatology</i> , 2020, 47, 1204-1208.	1.0	10
222	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. <i>Scientific Reports</i> , 2021, 11, 23335.	1.6	10
223	Characterisation of the genomic architecture of human chromosome 17q and evaluation of different methods for haplotype block definition. <i>BMC Genetics</i> , 2005, 6, 21.	2.7	9
224	Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort. <i>Arthritis and Rheumatism</i> , 2010, 62, 3827-3829.	6.7	9
225	No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1407-1408.	0.5	9
226	Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2010, 49, 43-47.	0.9	9
227	Rheumatoid arthritis response to treatment across IgG1 allotype “ anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015, 17, 63.	1.6	9
228	Rheumatoid arthritis patient perceptions on the value of predictive testing for treatments: a qualitative study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 460.	0.8	9
229	Replication of a distinct psoriatic arthritis risk variant at the IL23R locus. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1417-1418.	0.5	9
230	Previously reported “SLCO1C1” genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. <i>Pharmacogenomics</i> , 2016, 17, 715-720.	0.6	9
231	Genotypic variability-based genome-wide association study identifies non-additive loci HLA-C and IL12B for psoriasis. <i>Journal of Human Genetics</i> , 2018, 63, 289-296.	1.1	9
232	Latent Class Trajectory Modeling of “Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. <i>Arthritis and Rheumatology</i> , 2020, 72, 1632-1642.	2.9	9
233	ASSIMILATOR: a new tool to inform selection of associated genetic variants for functional studies. <i>Bioinformatics</i> , 2011, 27, 144-146.	1.8	8
234	Economics of Stratified Medicine in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 468.	2.1	8

#	ARTICLE	IF	CITATIONS
235	Investigation of an interleukin-6 receptor gene polymorphism (rs2228145) as a predictor of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 787-788.	0.5	8
236	Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2099-2102.	0.5	8
237	Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 735-741.	2.9	8
238	Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as "satisfactory". <i>Rheumatology</i> , 2020, 59, 1853-1861.	0.9	8
239	Using functional genomics to advance the understanding of psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, 3137-3146.	0.9	8
240	Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors?. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 389-396.	1.3	8
241	TNFR2 is not associated with rheumatoid arthritis susceptibility in a Caucasian population. <i>Arthritis and Rheumatism</i> , 2005, 52, 2579-2581.	6.7	7
242	Fine mapping of genes within the IDDM8 region in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2006, 8, R145.	1.6	7
243	Examining the overlap between genome-wide rare variant association signals and linkage peaks in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 1522-1526.	6.7	7
244	Rheumatoid Arthritis-associated Polymorphisms at 6q23 Are Associated with Radiological Damage in Autoantibody-positive RA. <i>Journal of Rheumatology</i> , 2012, 39, 1781-1785.	1.0	7
245	The skin microbiome in psoriatic arthritis: methodology development and pilot data. <i>Lancet, The</i> , 2015, 385, S27.	6.3	7
246	The Single-Nucleotide Polymorphism Lottery: How Useful are a Few Common SNPs in Identifying Disease-Associated Alleles?. <i>Genetic Epidemiology</i> , 2001, 21, S384-9.	0.6	6
247	Genetic epidemiology of psoriatic arthritis. <i>Modern Rheumatology</i> , 2004, 14, 91-100.	0.9	6
248	Investigation of association of genes NAT9, SLC9A3R1 and RAPTOR on chromosome 17q25 with psoriatic arthritis: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 292-293.	0.5	6
249	Biomarkers of outcome in rheumatoid arthritis. <i>Rheumatology Reports</i> , 2010, 2, 3.	0.1	6
250	Testing the role of vitamin D in response to antitumour necrosis factor $\hat{\pm}$ therapy in a UK cohort: a Mendelian randomisation approach. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 938-940.	0.5	6
251	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. <i>Arthritis Research and Therapy</i> , 2015, 17, 359.	1.6	6
252	Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 516-523.	0.9	6

#	ARTICLE	IF	CITATIONS
253	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. <i>Rheumatology</i> , 2021, 60, 125-131.	0.9	6
254	Approaches to Identifying Genetic Predictors of Clinical Outcome in Rheumatoid Arthritis. <i>Molecular Diagnosis and Therapy</i> , 2003, 3, 181-191.	3.3	5
255	Dissection of Complex Genetic Disease. <i>Clinical Orthopaedics and Related Research</i> , 2004, 419, 297-305.	0.7	5
256	Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?. <i>Rheumatology</i> , 2021, 60, 4633-4642.	0.9	5
257	Genetics and the impact on treatment protocols in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 509-511.	1.3	4
258	Cell-specific epigenetic drivers of pathogenesis in rheumatoid arthritis. <i>Epigenomics</i> , 2021, 13, 549-560.	1.0	4
259	Genetic epidemiology of psoriatic arthritis. <i>Modern Rheumatology</i> , 2004, 14, 91-100.	0.9	4
260	Investigation of C reactive protein gene polymorphisms as predictors of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1429-1430.	0.5	3
261	THU0010â€¦A Weighted Genetic Risk Score Using 46 Loci to Predict Rheumatoid Arthritis Risk. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A167.3-A168.	0.5	3
262	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Pharmacogenomics Journal</i> , 2014, 14, 171-175.	0.9	3
263	Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. <i>Pharmacogenomics</i> , 2020, 21, 1151-1156.	0.6	3
264	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. <i>Rheumatology</i> , 2022, 61, 4935-4944.	0.9	3
265	HLA-DRB1 haplotypes predict cardiovascular mortality in inflammatory polyarthritis independent of CRP and anti-CCP status. <i>Arthritis Research and Therapy</i> , 2022, 24, 90.	1.6	3
266	Linkage analysis of cross-sectional and longitudinally derived phenotypic measures to identify loci influencing blood pressure. <i>BMC Genetics</i> , 2003, 4, S26.	2.7	2
267	Investigation of association of the DLG5 gene with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 273-274.	0.5	2
268	THU0003â€¦CD4+ and B lymphocyte expression quantitative traits at rheumatoid arthritis risk loci in untreated early arthritis: implications for causal gene identification?. , 2017, , .		2
269	Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach. <i>Clinical Proteomics</i> , 2021, 18, 20.	1.1	2
270	The epidemiology of rheumatoid arthritis and the use of linkage and association studies to identify disease genes. , 2006, , 9-28.		2

#	ARTICLE	IF	CITATIONS
271	Genetic predictors of response to anti-tumor necrosis factor drugs in rheumatoid arthritis. <i>Rheumatology Reports</i> , 2009, 1, 1.	0.1	1
272	Rheumatoid Arthritis: Treatment [151-201]: 151. Should we be Looking More Carefully for Methotrexate Induced Liver Disease?. <i>Rheumatology</i> , 2010, 49, i89-i111.	0.9	1
273	Idiopathic Orbital Inflammation Successfully Treated Using Rituximab in a Patient with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 1907-1907.	1.0	1
274	SAT0012â€¦Estimating heritability of response to treatment with anti-TNF biologic agents using linear mixed models. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 474.3-475.	0.5	1
275	AB0289â€¦Can cd11c expression successfully predict response to etanercept in rheumatoid arthritis patients?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A875.1-A875.	0.5	1
276	OP0050â€¦Fine Mapping and Expression of a Locus Overlapping 3 Types of Inflammatory Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A66.3-A67.	0.5	1
277	SAT0345â€¦Lifestyle, Clinical and Psychosocial Predictors of Good Response to Methotrexate Therapy in the Rheumatoid Arthritis Medication Study (RAMS). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 783.3-784.	0.5	1
278	O53.â€¦PTPN22 is Associated with Susceptibility to Psoriatic Arthritis but not Psoriasis: Evidence for a Further PSA-Specific Risk Locus. <i>Rheumatology</i> , 2015, , .	0.9	1
279	AB0727â€¦Increased Rates of Hypertension in Patients with Psoriatic Arthritis Compared To Psoriasis Alone: Results from The UK Biobank: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1153.1-1153.	0.5	1
280	Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment. <i>Patient</i> , 2022, 15, 109-119.	1.1	1
281	P189â€¦A longitudinal study of psychological predictors of response to adalimumab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	1
282	Syntenic mapping of human disease genes using animal models of autoimmunity. <i>GeneScreen</i> , 2000, 1, 3-7.	0.7	0
283	Commentary on "Genetic linkage and transmission disequilibrium of marker haplotypes at chromosome 1q41 in human systemic lupus erythematosus", by RR Graham et al. <i>Arthritis Research</i> , 2002, 4, 84.	2.0	0
284	Association of the FCRL3 gene with rheumatoid arthritis: a further example of population specificity?. <i>Arthritis Research and Therapy</i> , 2008, 10, 405.	1.6	0
285	Genetics [315-318]: 315. Investigation of Association of the Erap1 Gene with Psoriatic Arthritis. <i>Rheumatology</i> , 2010, 49, i152-i154.	0.9	0
286	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. <i>Human Molecular Genetics</i> , 2010, 19, 4544-4544.	1.4	0
287	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. <i>Human Molecular Genetics</i> , 2010, 19, 4543-4543.	1.4	0
288	Concurrent Oral 6 - Spondylarthropathies [OP40-OP47]: OP40. Association of IL23R and IL12B Polymorphisms with Psoriatic Arthritis. <i>Rheumatology</i> , 2010, 49, i17-i20.	0.9	0

#	ARTICLE	IF	CITATIONS
289	OP0213â€¦Identification of common susceptibility loci for inflammatory arthritis. Annals of the Rheumatic Diseases, 2013, 71, 128.1-128.	0.5	0
290	AB0180â€¦Relationship between area level socio-economic deprivation and autoantibody status in rheumatoid arthritis patients: Multicentre cross-sectional study. Annals of the Rheumatic Diseases, 2013, 71, 647.17-647.	0.5	0
291	SAT0007â€¦Fine-mapping of the 5Q31 psoriatic arthritis susceptibility LOCI in a british population. Annals of the Rheumatic Diseases, 2013, 71, 473.1-473.	0.5	0
292	THU0002â€¦Fine mapping and expression studies of the 12Q13-14 locus associated with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 154.2-154.	0.5	0
293	SAT0014â€¦Correlation of CRP haplotypes with response to anti-TNF therapy in UK patients â€œ results from the BRAGGSS cohort. Annals of the Rheumatic Diseases, 2013, 71, 475.2-475.	0.5	0
294	OP0210â€¦Enrichment of vitamin D response elements in RA associated loci, suggests a role for vitamin D in the pathogenesis of RA. Annals of the Rheumatic Diseases, 2013, 71, 126.3-127.	0.5	0
295	OP0214â€¦Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study (ERAS) provides further replication of the TRAF1/C5 association with radiological damage. Annals of the Rheumatic Diseases, 2013, 71, 128.2-128.	0.5	0
296	THU0174â€¦Impact of IL-6R and IL-6ST Polymorphisms on Response to Anti-TNF Therapy in UK Patients â€œ Results from the Braggss Cohort. Annals of the Rheumatic Diseases, 2013, 72, A222.1-A222.	0.5	0
297	THU0003â€¦Fine-mapping of autoimmune susceptibility LOCI using immunoChip identifies novel susceptibility LOCI for psoriatic arthritis. Annals of the Rheumatic Diseases, 2013, 71, 154.3-155.	0.5	0
298	AB0436â€¦Patient acceptable symptom state in rheumatoid arthritis patients starting methotrexate correlates with age and patient reported outcomes. Annals of the Rheumatic Diseases, 2013, 71, 662.9-662.	0.5	0
299	A7.15â€¦Lack of Association of Variants Previously Associated with Anti-TNF Medication Response in Rheumatoid Arthritis Patients: Results from a Homogeneous Greek Population. Annals of the Rheumatic Diseases, 2013, 72, A53.1-A53.	0.5	0
300	SAT0095â€¦Control of Disease Activity is Associated with Improvement in Physical Activity in Patients with Rheumatoid Arthritis: Table 1. Annals of the Rheumatic Diseases, 2014, 73, 624.3-625.	0.5	0
301	Do lean markers relate to exacerbation rate in chronic obstructive pulmonary disease? Preliminary results from AERIS study. Proceedings of the Nutrition Society, 2015, 74, .	0.4	0
302	054.â€¦The Importance of IL-6-STAT3 Mediated Activation of Circulating CD4<sup>+</sup> T Cells in the Pathogenesis of Early Seronegative Rheumatoid Arthritis: A Validation Study. Rheumatology, 2015, , .	0.9	0
303	Reply. Arthritis Care and Research, 2015, 67, 452-453.	1.5	0
304	O10.â€¦Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2015, , .	0.9	0
305	O49.â€¦Personalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 Predict Disease Severity, Mortality and Treatment Response in Rheumatoid Arthritisâ€œ Multi-Centre Prospective Cohort Studies. Rheumatology, 2015, , .	0.9	0
306	OP0235â€¦Identification of Novel Cd4+ Lymphocyte Expression Quantitative Trait Loci in Untreated Early Arthritis Patients. Annals of the Rheumatic Diseases, 2016, 75, 147.1-147.	0.5	0

#	ARTICLE	IF	CITATIONS
307	SAT0009â€¦Investigation of Differential Methylation as A Potential Biomarker of Methotrexate Response in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 667.1-667.	0.5	0
308	Cryopreservation of cells does not substantially alter the DNA methylome of CD3+CD4+ T cells. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 329-330.	0.6	0
309	A6.13â€¦Identification of novel expression quantitative trait loci in CD4+T cells of untreated early arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A52.2-A52.	0.5	0
310	AB0005â€¦Weighted Gene Co-Expression Network Analysis Reveals Link between Protein Kinase Signalling and Response To Methotrexate in New-Onset Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 898.2-898.	0.5	0
311	05.10â€¦Comparison of cd4+ and b lymphocyte expression quantitative trait associations at ra risk loci in untreated early arthritis patients. , 2017, , .		0
312	THU0001â€¦Differential methylation as a potential biomarker of methotrexate response in patients with rheumatoid arthritis. , 2017, , .		0
313	THU0004â€¦Cross phenotype association mapping of the mhc identifies genetic variants that differentiate psoriatic arthritis from psoriasis. , 2017, , .		0
314	OP0298â€¦Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases. , 2017, , .		0
315	FRI0724â€¦Predictors of presenteeism and absenteeism in patients commencing treatment with methotrexate monotherapy or biologic therapy for rheumatoid arthritis. , 2017, , .		0
316	Genetics of Rheumatic Diseases. , 2017, , 327-343.		0
317	O12â€¦Validity of a2-component imaging-derived disease activity score (2C-DAS28) for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
318	248â€¦Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
319	227â€¦Predictors of presenteeism and absenteeism in patients commencing treatment with methotrexate monotherapy or biologic therapy for rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
320	e11â€¦Patterns of the patient acceptable symptom state over 12 months following the initiation of methotrexate therapy in patients with rheumatoid arthritis, and the association between these patterns and disability and disease activity. <i>Rheumatology</i> , 2018, 57, .	0.9	0
321	P124â€¦Altered CD4+ T cell DNA methylation in early rheumatoid arthritis. , 2018, , .		0
322	089â€¦The association between poor prognostic factors at methotrexate initiation and disease activity and disability over one year: results from the Rheumatoid Arthritis Medication Study. <i>Rheumatology</i> , 2018, 57, .	0.9	0
323	e12â€¦Clinical phenotypes of patients with rheumatoid arthritis who identify as in a patient acceptable symptom state at methotrexate initiation and a comparison of the outcome of these phenotypes over 12 months. <i>Rheumatology</i> , 2018, 57, .	0.9	0
324	Psoriasis and Psoriatic Arthritis. , 2018, , 239-250.		0

#	ARTICLE	IF	CITATIONS
325	O58â€fInvestigating the pharmacogenetics of anti-TNF response in patients with rheumatoid arthritis utilising the re-weighted disease activity score: results from the biologics in rheumatoid arthritis genetics and genomics study syndicate. <i>Rheumatology</i> , 2019, 58, .	0.9	0
326	I051â€fWhat do we mean by treatment response and can we predict it?. <i>Rheumatology</i> , 2019, 58, .	0.9	0
327	O55â€fCan interleukin IL-17A levels predict response to biologic treatment in patients with rheumatoid arthritis?. <i>Rheumatology</i> , 2019, 58, .	0.9	0
328	SAT0062â€f...STRATIFIED MEDICINE FOR RHEUMATOID ARTHRITIS: PREDICTING RESPONSE TO BIOLOGIC THERAPY USING IMMUNE CELL SIGNATURES. , 2019, , .		0
329	P106/O25â€f...DNA methylation in lymphocyte subsets as a mediator of genetic risk in early rheumatoid arthritis. , 2019, , .		0
330	FRIO004â€f...CHROMATIN INTERACTIONS IN NOVEL CELL TYPES REVEAL PARK7 AND ERRF1 AS PUTATIVE CAUSAL GENES IN THE SUSCEPTIBILITY TO PSORIATIC ARTHRITIS. , 2019, , .		0
331	Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICEâ€™s recommendations. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa023.	0.3	0
332	O11â€fLymphocyte DNA methylation mediates genetic risk at RA risk loci that are shared with other immune mediated diseases. <i>Rheumatology</i> , 2020, 59, .	0.9	0
333	O08â€fDeveloping a DNA methylation signature for predicting rheumatoid arthritis using a machine learning pipeline. <i>Rheumatology</i> , 2021, 60, .	0.9	0
334	THU0001â€f...Differential methylation as a predictor of methotrexate response in patients with rheumatoid arthritis. , 2018, , .		0
335	THU0022â€f...DIFFERENTIAL DNA METHYLATION AS A PREDICTOR OF TOCILIZUMAB RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 224.1-224.	0.5	0
336	THU0005â€f...VARIABILITY OF DNA METHYLATION IS A DRIVER OF LYMPHOCYTE DYSREGULATION IN EARLY RHEUMATOID ARTHRITIS.. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 215.2-215.	0.5	0
337	P200â€fCombining protein quantitative trait and genetic risk score analysis to identify biomarkers of treatment response to TNFi in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
338	OA24â€fPredicting drug immunogenicity to tumour necrosis factor inhibitors in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
339	P190â€fUnsupervised automated clustering of mass cytometry data identifies unique CD4+ T cell subsets in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
340	OA15â€fDrivers of change in four and two component disease activity scores after etanercept treatment, in a multi-centre cohort of patients with established rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
341	OA28â€fExploring the potential of polygenic risk scores for predicting coronary artery disease in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
342	OA16â€fTherapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort. <i>Rheumatology</i> , 2022, 61, .	0.9	0